Acura Pharmaceuticals to Report Fourth Quarter and Fiscal Year 2011 Financial Results
(firmenpresse) - PALATINE, IL -- (Marketwire) -- 02/23/12 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating , today announced that the company plans to report financial results for the fourth quarter and fiscal year 2011 following the close of markets on Monday, March 5, 2012. The company will host a conference call to discuss the results on Tuesday, March 6, 2012 at 8:30 a.m. ET.
To access the live call, dial 888-297-0360 (U.S. and Canada), or 719-325-2352 (international) five to ten minutes prior to the start of the call. The participant passcode is 8695304. A live audio webcast will also be available in the "Investors" section of the company's website, .
A replay of the call will be available beginning March 6, 2012 at 11:30 a.m. ET and ending on March 20, 2012 on the company's website, and by dialing 888-203-1112 (U.S. and Canada) or 719-457-0820 (international). The replay participant code is 8695304.
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address , utilizing its proprietary AVERSION® and IMPEDE technologies. In June 2011, the U.S. Food and Drug Administration, or FDA, approved OXECTA® which incorporates the AVERSION technology. The Company has a development pipeline of additional AVERSION technology products including other opioids, stimulants and benzodiazepines and its IMPEDE technology for pseudoephedrine hydrochloride products.
Contact:
212-867-1762
917-660-0608
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.02.2012 - 16:30 Uhr
Sprache: Deutsch
News-ID 117983
Anzahl Zeichen: 0
contact information:
Town:
PALATINE, IL
Kategorie:
Security
Diese Pressemitteilung wurde bisher 241 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Acura Pharmaceuticals to Report Fourth Quarter and Fiscal Year 2011 Financial Results"
steht unter der journalistisch-redaktionellen Verantwortung von
Acura Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
